All existing shareholders contributed to the Marine Biological Laboratory spinout’s series B round, following a $91.5m series A in mid-2020.

Korro Bio, a US-based RNA editing technology developer based on research at University of Chicago-affiliated Marine Biological Laboratory, secured $116m in series B financing led by Eventide Asset Management last week. Fidelity Management & Research, Invus, Point72, Verition Fund Management, Monashee Investment Management, Sixty Degree Capital and an unnamed healthcare specialist fund invested in the…

The rest of this content is only accessible to Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.